SKYX Revenues Increased for 7 Consecutive Comparable Quarters from Q1 2024 Through Q3 2025 with $19M in Q1/24, $21M in Q2/24, $22M in Q3/24, $23M in Q4/24, $20M in Q1/25, $23M in Q2/25 and $24M in Q3/25 Gross Profit Improvement by 8% to $8.0 million in the Third Quarter… Read More..

HOUSTON, November 12, 2025--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (Coya or the Company), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function in patients with neurodegenerative disorders, provides a corporate update and announces its financial results for the quarter ended September 30, 2025. Recent… Read More..

Quoin Pharmaceuticals Announces Corporate Update and Third Quarter 2025 Financial Results PDF Version – Private Placement Financing of Up to $105.3 Million Closed in October 2025 to Fund Operations and R&D – Sally Lawlor Appointed CFO to Support Commercialization and Financial Operations – Orphan Drug Designation Awarded by FDA to… Read More..